Role of taxanes in pancreatic cancer

Carmen Belli, Stefano Cereda, Michele Reni

Carmen Belli, Stefano Cereda, Michele Reni, Department of Oncology, San Raffaele Scientific Institute, 20132 Milan, Italy

Author contributions: Reni M conceived the paper and critically reviewed the data and the final version; Cereda S contributed to the analysis and interpretation of data; Belli C drafted the article and revised it critically for important intellectual content; and all authors approved the final version.

Correspondence to: Michele Reni, MD, Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy. reni.michele@hsr.it

Telephone: +39-2-26437644 Fax: +39-2-26437625

Received: January 9, 2012 Revised: April 9, 2012

Abstract
Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

© 2012 Baishideng. All rights reserved.

Key words: Pancreatic cancer; Advanced disease; Metastatic disease; Chemotherapy; Taxanes; Drug combinations; Radiotherapy; ABI-007

INTRODUCTION
Pancreatic cancer has a very poor prognosis and it still remains as one of the most deadly cancers. At diagnosis, only 10%-20% of patients are considered candidates for a curative resection that is possible only in the absence of distant metastases, peritoneal carcinomatosis, and lack of any involvement of celiac axis and superior mesenteric artery[1]. Around 80% of patients have advanced or metastatic disease and median overall survival (mOS) of this group is very poor ranging from 3 to 6 mo[2]. The first drug used in the treatment of advanced pancreatic cancer was 5-fluorouracil (5-FU) that provided a palilative benefit with a significant improvement in mOS compared to best supportive care (6 mo vs 2.5 mo, P < 0.01)[3]. The first drug used in the treatment of advanced pancreatic cancer was 5-fluorouracil (5-FU) that provided a palliative benefit with a significant improvement in mOS compared to best supportive care (6 mo vs 2.5 mo, P < 0.01)[3]. The first drug used in the treatment of advanced pancreatic cancer was 5-fluorouracil (5-FU) that provided a palliative benefit with a significant improvement in mOS compared to best supportive care (6 mo vs 2.5 mo, P < 0.01)[3].
taxel) were tested as single agents or in combination with other chemotherapeutic agents in pancreatic cancer because they showed promising activity in other solid tumours. Mechanism of action of these drugs consists in enhancing microtubule assembly and inhibiting the depolymerization of tubulin responsible for the formation of bundles of microtubules blocking cell proliferation.

This article summarises the main clinical studies conducted in pancreatic cancer with taxanes as first or second line chemotherapy, both as monotherapy and combination therapy, in order to clarify the potential role of this class of drugs for further investigations.

**DOCETAXEL**

**First-line therapy**

**Single agent:** Docetaxel gained researchers’ attention for the treatment of pancreatic cancer after a preclinical study showed its effectiveness in a murine model of pancreatic ductal adenocarcinoma. Docetaxel activity as single agent was assessed in phase II trials in chemonaïve patients affected by pancreatic cancer at two different dosages, 60 mg/mq and 100 mg/mq, showing promising activity when used at higher dose (Table 1). With higher doses, the overall RR ranged from 5% to 15%, the median time to progression (mTTP) was 2.1-5.0 mo, and the mOS was 7-8.5 mo. Neutropenia was the most frequently observed grade 3/4 toxicity in both studies (30%-95%). Grade 3-4 anemia (9%-16%) and fatigue (9%-23%) were also commonly reported. Given the phase II nature of the trials, the small sample size and the selection of patient population, including stage II and III disease and patients who mainly had a performance status of 0-1, these results should be interpreted with caution. Nevertheless, these trials showed that docetaxel has some activity in the treatment of pancreatic cancer, and warrant further exploration. Docetaxel administered at lower dose failed to demonstrate any activity in pancreatic cancer. In fact, no objective response was observed and both mTTP and mOS were shorter when compared to higher doses. Moreover, grade 3-4 toxicity was remarkable with nearly 80% of the patients developing neutropenia, 7% anemia, and 27% fatigue.

**Combination chemotherapy:** Docetaxel role was also addressed in combination with other drugs (Table 1). *In vitro* and *in vivo* studies have demonstrated that docetaxel yields a synergism with other drugs like capcitabine, 5-FU, gemcitabine, and cisplatin. The rationale for the combination of an oral fluoropyrimidine with docetaxel is based on the ability of taxanes to increase the activity in the tumoral tissue of thymidine phosphorylases, which are key enzymes in the transformation process of capcitabine into its active metabolite 5-FU. The synergism of docetaxel with gemcitabine was observed in *in vitro* in several cancer cell lines, but the biological mechanism is not clear. Hypothetically, the combination of these two agents could regulate the apoptotic process by increasing the apoptotic index. Finally, the synergism of docetaxel and cisplatin, observed in cell lines of gastric cancer, could be due to the down-regulation of multi drug resistant proteins by docetaxel thereby increasing cytotoxic index of cisplatin.

Several phase II clinical trials assessed the activity of these combinations against advanced pancreatic cancer as an upfront therapy. Docetaxel and gemcitabine yielded promising RR ranging from 12% to 40% and mOS ranging from 6 to 9 mo. However, these single arm findings cannot be considered conclusive. Interestingly, the European Organization for Research and Treatment of Cancer (EORTC) group conducted a phase II trial in which 96 patients were randomized to receive gemcitabine plus docetaxel or cisplatin plus docetaxel. In 70 patients who were assessable for response, the RR was 19.4% with gemcitabine-docetaxel combination and 23.5% with cisplatin-docetaxel combination. Conversely, survival figures were better in 49 patients treated by the gemcitabine-docetaxel combination [median progression free survival (mPFS) 3.9 mo, mOS 7.4 mo; 1-year OS 30%] compared to those receiving cisplatin-docetaxel (mPFS 2.8 mo, mOS 7.1 mo; 1-year OS 16%). Toxicity was not negligible, consisting of grade 3-4 neutropenia in 47% and 55%, and febrile neutropenia in 9% and 16%, respectively. Altogether, safety profile and survival analysis favoured gemcitabine-docetaxel combination for further evaluation. Another phase II trial randomized 259 patients with metastatic pancreatic cancer to receive fixed dose gemcitabine or gemcitabine combined with either docetaxel, cisplatin, or irinotecan. The primary end point of this study was the six months OS that was similar in all four treatment arms: 57% for fixed gemcitabine dose, 53% for gemcitabine plus cisplatin, 54% for gemcitabine plus docetaxel, and 57% for gemcitabine plus irinotecan. The mOS and mTTP were similar in the treatment groups and ranged between 6.4-7.1 mo and 3.3-4.5 mo, respectively. The RRs were also indistinguishable among treatment groups and ranged between 12% to 14%. The cisplatin and docetaxel combination tested in this study gave similar results, in terms of mOS and TTP, to that reported in the EORTC trial.

Another drug tested in combination with docetaxel was liposomal doxorubicin starting from preclinical study conducted on xenografted human pancreatic carcinoma in which this drug demonstrated to reduce tumor growth with a low toxicity. In a phase II clinical trial, this combination was studied on twenty-one locally advanced and metastatic pancreatic cancer patients. The results in terms of RR (21%) and mOS (10 mo) were similar to those observed with combination of docetaxel with other drugs.

The activity of docetaxel, gemcitabine, capcitabine regimen (GTX) was also tested in 43 patients with metastatic disease yielding a RR of 22% and a mOS of 14.5 mo. These results were echoed in a recent retrospective study on 79 chemonaïve patients with locally advanced or metastatic pancreatic cancer who had a mOS...
Table 1 Clinical trials of docetaxel in pancreatic cancer

| Trial                  | CT agent | Line | N. of patients | RR %   | mPFS (mo) | mOS (mo) | Toxicity % |
|------------------------|----------|------|----------------|--------|-----------|----------|------------|
| Okada et al[31]        | Doce     | 1    | 21             | CR 0   | 11        | 6        | Neutropenia 86, anemia 10, thrombocytopenia 5, asthenia 33, nausea-vomiting 29 |
| Androulakis et al[32]  | Doce     | 1    | 33             | CR 3   | 51        | 8.5      | Neutropenia 36, febrile neutropenia 6, anemia 9, asthenia 9, neuropathy 6 |
| Rougier et al[33]      | Doce     | 1    | 43             | CR 0   | 2.1       | 7        | Neutropenia 95, febrile neutropenia 9, anemia 16, asthenia 23, vomiting 7 |
| Stathopoulos et al[34] | Doce + GEM | 1    | 54             | CR 0   | 8         | 6        | Neutropenia 31, febrile neutropenia 11, thrombocytopenia 7, asthenia 13, diarrhea 6 |
| Ryan et al[35]         | Doce + GEM | 1    | 33             | CR 0   | 3.8       | 8.9      | Neutropenia 49, febrile neutropenia 12, asthenia 27, nausea-vomiting 12, diarrhea 12, neuropathy 9 |
| Lutz et al[36]         | Doce + GEM | 1    | 96             | CR 0/2.9 | 3.9/2.8 | 7.4/7.1 | Neutropenia 40/50, febrile neutropenia 9/16, anemia 20/9, thrombocytopenia 8/5, diarrhea 8/5, stomatitis 8/10 |
| Kulke et al[37]        | GEM + CDDP | 1    | 259            | CR 2/0/0/2 | 4.5/3.3/4.1/4.0 | 6.7/6.4/6.4/7.1 | Neutropenia 46/48/31/25, febrile neutropenia 2/3/5/2, anemia 16/12/16/5, thrombocytopenia 49/25/9/14, asthenia 16/14/21/19, nausea-vomiting 41/26/17/25, diarrhea 80/2/8/8 |
| Fine et al[38]         | GTX      | 1    | 43             | CR 0   | 6.9       | 14.5     | Neutropenia 29.2, thrombocytopenia 12.2, mucositis 7.5 |
| Reni et al[39]         | PDXG     | 1    | 105            | CR 2/4 | 7.4/7.6   | 10.7/11  | Neutropenia 4/13, thrombocytopenia 2/4, anemia 4/4, asthenia 6/3 |
| Cereda et al[40]       | Doce     | II   | 10             | CR 0   | 1.5       | 4        | Not observed |
| Katopodis et al[41]    | Doce + X | II   | 31             | CR 0   | 2.4       | 6.3      | Neutropenia 32.2, febrile neutropenia 3.2, anemia 3.2, thrombocytopenia 3.2, stomatitis 3.2, asthenia 6.5 |
| Reni et al[42]         | MDI      | II-III | 15            | CR 0   | 1.7       | 6.1      | Phase I study Neutropenia 23, fatigue, diarrhea, and vomiting 10 |

1mTTP: Median time to progression; CT: Chemotherapy; RR: Response rate; mPFS: Median progression free survival; mOS: Median overall survival; Doce: Docetaxel; GEM: Gemcitabine; CDDP: Cisplatin; CPT-11: Irinotecan; GTX: Gemcitabine + Taxotere + Xeloda; PDXG: Cisplatin + Docetaxel + Gemcitabine + Xeloda; GTX: Gemcitabine + Epirubicin + Xeloda + Gemcitabine; X: Xeloda; MDI: Mitomycin + Docetaxel + Irinotecan; CR: Complete response; PR: Partial response; SD: Stable disease.

of 25.0 and 11.3 mo, respectively[31].

A four drug combination of cisplatin, docetaxel, capecitabine, and gemcitabine (PDXG) was tested in a randomized phase II trial in which a cisplatin, epirubicin, capecitabine, and gemcitabine (PExG) regimen was chosen as calibration arm[22]. This choice was based on the fact that a PEFG regimen (cisplatin, epirubicin, fluorouracil, and gemcitabine) was previously shown to be superior to gemcitabine monochemotherapy in terms of progression free survival [PFS; hazard ratio (HR) 0.51; range 0.33-0.78] and OS (HR 0.65; range 0.43-0.99) in a phase III trial of first line therapy of pancreatic cancer[23] and that the use of oral capecitabine was shown to be equivalent to 5-FU in other tumors[33]. Both the radiological and the biochemical RR[44] were better for 53 patients treated with PDXG (60% complete plus partial radiological responses; 41% major biochemical responses; 39% minor biochemical responses) than for 52 patients receiving PEXG (37% complete plus partial radiological responses; 32% major biochemical responses; 32% minor biochemical responses). However, OS and PFS were very similar in the two arms (mOS 10.7 mo vs 11.0 mo and mPFS 7.4 mo vs 7.6 mo, with PDXG and PEXG regimens, respectively). The safety profile of PDXG regimen was more favourable than that of PEXG regimen in terms of grade 3-4 neutropenia (4% in PDXG group vs 13% in PEXG arm).

Overall, these studies suggest that multi-drug associations, in particular triplets and quadruplets, are more active in pancreatic cancer when compared to monochemotherapy.

**Salvage therapy**

**Single agent and combination chemotherapy**: Docetaxel was also tested as salvage treatment in pancreatic cancer both as single agent and in combination[31,35-45].
Combination chemotherapy: EndoTAG™-1 (ET) is a cationic liposome membrane charging paclitaxel. This particular structure promotes the delivery of the drug in the tumor mass. Tumor endothelium lacks glycosaminoglycan which normally covers endothelial cells, so negative charges are exposed on the cell surface. Thus, the positive charges carried by liposomes is exposed and interact with the negative charges present on tumoral cells favouring the internalization of the drug into the tumor.

Löhr et al. tested ET in combination with gemcitabine vs gemcitabine alone in a four-arm randomized phase II trial on 212 patients affected by locally advanced or metastatic disease (Table 2). The treatment consisted of seven weekly infusions of standard gemcitabine alone or associated with twice-weekly ET at dosage of 11 (Endo11), 22 (Endo22) or 44 mg/mq (Endo44) for seven weeks. RR was comparable across the four treatment groups (14%-16%), the mPFS was longer in the gemcitabine plus ET arms (4.1, 4.6, and 4.4 for Endo11, Endo22, and Endo44, respectively) compared to gemcitabine group (2.7 mo). Also the mOS appeared to be better in the combination arms (from 8.1 to 9.3 mo) compared to single agent (mOS 6.8 mo). The treatment with gemcitabine and ET was well tolerated with a dose-dependent increase in grade 3-4 thrombocytopenia (from 8% to 14%), neutropenia (from 12% to 22%), and anemia (from 4% to 8%). Grade 3-4 febrile neutropenia was observed in 6% of the patients. No treatment-related neuropathy was observed in this trial. This study suggested that this new formulation of paclitaxel warrants further investigation to define its role in the treatment of pancreatic cancer.

Another paclitaxel formulation known as ABI-007 was tested against pancreatic cancer. ABI-007 (also...
known as nab-paclitaxel), is a cremophor-free, albumin-bound 130-nm particle form of paclitaxel that does not require the use of cremophor-EL, thus avoiding the severe toxicities associated with this vehicle\[^{10}\]. The albumin in nab-paclitaxel binds to gp60 (albondin) receptors and to caveolae resulting in the formation of caveoli transporting the drug across the endothelial cells to the tumor interstitial space. In pancreatic tumor stroma, secreted protein acid and rich in eystein (SPARC) protein, which is also called osteonectin, is overexpressed. SPARC interacts with the albumin of nab-paclitaxel enhancing the concentration of this drug into the tumor, which causes “stromal collapse”, a phenomenon of depletion and collapsing of stroma, bringing tumor cells closer to each other and to blood vessel. A phase IB-II study of ABI-007 in combination with gemcitabine was performed in metastatic pancreatic cancer (Table 2)\[^{54}\]. The maximum tolerated dose (MTD) was 125 mg/mq for ABI-007 in combination with standard gemcitabine\[^{59}\]. The PFS for the whole population of patients enrolled into the trial was 6.9 mo and the mOS was 10.3 mo, while in the group of 44 patients treated with ABI-007 at MTD, the mPFS was 7.9 mo and the mOS was 12.2 mo. A phase III clinical trial of gemcitabine and ABI-007 combination vs standard gemcitabine is currently ongoing in patients with metastatic pancreatic cancer (NCT00844649).

### Salvage therapy

**Single agent and combination chemotherapy:** ABI-007 at 100 mg/mq weekly for three weeks, out of every 4, was also tested as second line chemotherapy in 19 patients with progressive pancreatic cancer after previous gemcitabine-based therapy (Table 2)\[^{51}\]. One partial response (5.3%) and six stable disease (31.6%) were reported. The mPFS and mOS were 1.6 mo and 7.3 mo, respectively. Grade 3 or 4 neutropenia, neutropenic fever and anemia occurred in 32%, 11% and 11% of patients, respectively.

Paclitaxel in combination with 5-FU was administered as salvage therapy to 28 patients with advanced pancreatic cancer after gemcitabine failure (Table 2)\[^{82}\]. The RR was 10%, the mTTP 2.5 mo, and the mOS 7.6 mo. This regimen was well tolerated with grade 3-4 neutropenia in 21.4% of the patients, anemia in 3.6%, grade 4 neuropathy in 3.6%, and grade 3 diarrhea in 7.2% of the patients.

### TAXANES PLUS RADIOThERAPY

Pancreatic cancer is characterized by a high rate of both local and systemic failure. Chemoradiation was tested in stage III disease with different drugs yielding a mOS between 8 to 11 mo and 1-year survival rate between 25% to 40%\[^{13,25}\].

Due to their radiation-sensitizing properties\[^{86}\], taxanes were also tested in combination with radiotherapy in locally advanced\[^{37,58}\] and in resectable\[^{99}\] pancreatic cancer. In locally advanced disease, paclitaxel and radiotherapy obtained RR of 26%, mOS of 8-11.2 mo and 1-year OS of 30%-43%\[^{57,58}\]. These results were in the range reported with other drugs tested in combination with radiotherapy.

Conversely, paclitaxel-based chemoradiation as neoadjuvant therapy in resectable patients yielded disappointing results\[^{59}\]. In fact, 46% of the patients suffered grade 3 toxicity (hematological, gastrointestinal, asthenia, anorexia, allergic reaction) and the mOS (19 mo) was inferior than expected with 5-FU based chemoradiation (25 mo)\[^{60}\].

A phase II trial randomized 20 patients with resectable and unresectable disease to receive docetaxel plus either continuous 5-FU or weekly cisplatin concomitant to radiotherapy. The enrolment was prematurely concluded due to poor preliminary results\[^{41}\].

### CONCLUSION

Pancreatic cancer is characterized by a dismal prognosis and limited therapeutic progress has been achieved in the past 30 years. Due to its intrinsic or rapidly acquired chemoresistance, the therapeutic armamentarium against pancreatic cancer is limited and there is an urgent need to individuate new active agents or regimens. Single agent gemcitabine, despite poor activity and modest impact on disease outcome, is still considered the standard treatment both in early and advanced stages of the disease\[^{62}\]. Most combination regimens using gemcitabine-based doublets and including both conventional and targeted agents failed to significantly improve OS over gemcitabine alone\[^{57,31,36,46}\] or yielded a statistically significant but clinically negligible benefit\[^{52}\]. Interestingly, two phase III trials showed that drug combinations including more than two agents may improve OS when compared with gemcitabine alone\[^{32,56}\] and two clinical practice surveys suggested that the 4-drug regimens may be superior to gemcitabine/platinating-agent doublets\[^{47,57}\].

In particular, the PEFG regimen and the combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) yielded 1-year OS of 38%-48%\[^{32,66}\]. The results obtained with these regimens should be generalized with caution due to the lack of confirmatory trials and, in the case of FOLFIRINOX, to the highly selected patients population, which is evident on the basis of the better than expected standard arm outcome and because 4 years occurred to enrol 342 patients in 48 centers (≤2 pts/center per year)\[^{74}\]. Moreover, while PEFG toxicity profile was favourable\[^{32,68}\] and the regimen was in fact feasible also in the adjuvant setting\[^{33,65}\], grade 3-4 toxicity observed with FOLFIRINOX was remarkable particularly in the case of extra-hematological toxicity that may be barely acceptable in the context of a palliative therapy. In fact, the main reason for ending treatment was death in 85 (50%) patients in the FOLFIRINOX arm vs 75 in the gemcitabine arm, while fatigue was reported in 24% of the patients, vomiting in 15%, diarrhea in 13%, and neuropathy in 9%\[^{66}\]. Altogether, these results are encouraging and do suggest that a nihilistic attitude towards pancreatic cancer is not
longer justified and that more aggressive treatment approach may partially overcome chemoresistance. As previously observed with other drugs, like gemcitabine, 5-FU, capcitabine, pemtrexed, the use of taxanes as single agent treatment, both upfront and as salvage therapy, showed moderate activity but did not obtain exciting results. Not surprisingly and similarly to fluoropyrimidines and platinating agents, the inclusion of old generation taxanes in doublets with gemcitabine or cisplatin did not appear to produce better results than gemcitabine alone. On the other hand, the inclusion of taxanes in combination with more than 2 drugs seem to be more promising. Worth of note, unexpected radiological and biochemical response was observed in an exploratory subset analysis in patients with stage III disease (60% radiological response in PDXG group vs 37% in PEXG group and major plus minor biochemical response of 80% vs 64%, respectively). Furthermore, more patients in PDXG arm underwent to surgery with radical intent compared to PEXG arm (17% vs 6%) and neither resection margin nor nodal involvement was observed in the group treated with docetaxel. Furthermore, the new generation of taxanes, due to their unique chemical structure, are able to penetrate in tumor cell mass in high amount and apparently yields better activity than older taxanes. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

FUTURE PERSPECTIVES

Apart from the combination of ABI-007 with gemcitabine as first-line therapy in metastatic disease, which is currently being tested in a phase III trial (NCT00844649), the role of multiple (i.e., more than two drugs) agents regimens should be addressed. In fact, the hypothesis of stromal depletion induced by ABI-007, if confirmed, may provide a robust rationale for combination polychemotherapy, due to better drug penetration into tumor. Furthermore, a larger effect may be expected in primary tumor where the stroma is more abundant. A phase II clinical trial is evaluating a combination of ABI-007 with gemcitabine, and GDC-0049, a hedgehog inhibitor, in patients with untreated metastatic pancreatic cancer in order to evaluate the PFS and the safety of this combination (NCT01088815). The hedgehog signalling pathway is involved in embryonic development, but is also activated in pancreatic cancer. In preclinical model the inhibition of this pathway enhanced drug delivery to tumor cells by disrupting the desmoplastic stroma and increasing tumor vascularity. The combination of gemcitabine, ABI-007 and GDC-009 could enhance the stroma collapse and increase the intratumoral concentration of chemotherapeutic drugs. Accordingly, neoadjuvant therapy in patients with stage III disease, borderline resectable disease and resectable disease represents a potential field of investigation. Finally, ABI-007 may improve primary tumor oxygenation by inhibiting the formation of novel microvessels and by disrupting established microvessels thus increasing the therapeutic window of concomitant radiation therapy and targeted agents. So, the next logical step is to evaluate a combination of anti-angiogenic therapy with ABI-007 in metastatic setting. Furthermore, the identification of new prognostic markers like SPARC could help both in understanding the molecular changes responsible for development and progression of pancreatic cancer and in identifying a subset of patients in which taxane-based therapy may have a more relevant impact on the outcome.

REFERENCES

1. Li D, Xie K, Wolf R, Abbuzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057
2. Sener SF, Fremingen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7
3. Glimelius B, Hoffman K, Sjöden PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600
4. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Crippa MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
5. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adad F, Thompson J, Leonard P, Ostrowski J, Eateck M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518
6. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalanò P, Cella D, Benson AB. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (50-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785
7. Colucci G, Labianca R, Di Costanzo F, Gobbia V, Carteni G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciappafra M, Cavanna L, Giuliani F, Maieolo E, Testa A, Pedezzoli P, Falcioni M, Gallo C, Di Maio M, Perrone F. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28: 1645-1651
8. Okada S, Sakata Y, Matsumoto S, Kurihara M, Sasaki Y, Ohashi Y, Taguchi T. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999; 80: 438-443
9. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulas V. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17: 1779-1785

www.wjgnet.com
10 Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15: 2414-2419

11 Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005; 6: 229-239

12 Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007; 6: 609-621

13 Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13: 134-136

14 Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-2655

15 Rougier P, Adenis A, Dureux M, de Forni M, Bonnetere J, Demberk M, Clouet P, Lebecq A, Baillé P, Lefresne-Souflas F, Blanc C, Armand JP. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36: 1016-1025

16 Venturini M, Durando A, Gazzone O, Colozzo MA, Contu A, Stevani I, Genta F, Bighin C, Lambiase A, Del Mastro L. Capcitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 2003; 97: 1174-1180

17 Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capcitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019

18 Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Michelet S, Pilk D, Scholz C, Dörken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, capcitabine, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23: 494-501

19 Schneider GP, Gangoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C, Loehrer PJ. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003; 65: 218-223

20 Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001; 60: 316-321

21 Maeda S, Sugita T, Saikawa Y, Kubota T, Otani Y, Kumai K, Kitajima M. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 2004; 95: 679-684

22 Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Dogliani C, Villa E. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capcitabine, gemcitabine plus either epirubicin or docetaxel (PEX or PDGX regimen). Cancer Chemother Pharmacol 2012; 69: 115-123

23 Stathopoulos GP, Mavromdis D, Tsavaris N, Konouroussis C, Aravantinos G, Agekali S, Kakolyris S, Rigatos SK, Karabekios S, Georgoulias V. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12: 101-103

24 Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefuer U, Wilf JA, Camelin E, Koeneh CH, Arnaud JP, Mitry E, Hussein F, Reichardt P, El-Seraf M, Etienne PL, Lingenfelter T, Praet M, Genicot B, Debois M, Nordlinger B, Dureux MP. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomised phase II study 40364 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 2005; 23: 9250-9256

25 Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shvidasani R, Kim H, Mayer RJ, Clark JW. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94: 197-199

26 Xenidis N, Chelis L, Amarantidis K, Camaluido E, Dimopoulos P, Courcoutsakis N, Tentes A, Chiotis A, Prassopoulou S, Kakolyris S. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemother Pharmacol 2012; 69: 477-484

27 Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusimor M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009; 27: 5506-5512

28 Vaage J, Donovan D, Uster P, Working P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic cancer. Br J Cancer 1997; 75: 482-486

29 Syrigos KN,Michalaki B,Alevyazaki F, Machairas A, Mandrekas D, Kindilidis K, Karatzas G. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 2002; 22: 3583-3588

30 Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Provda J, Schreibman S, Levite J. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol 2009; 27 Suppl 15: abstr 4623

31 De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman S, Flores EI, Wilfong LS, Zheng L, Donohower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012; 69: 415-424

32 Reni M, Cordello S, Milandri C, Passoni P, Bonetto E, Oliani C, Lupp G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-376

33 Cunningham D, Starring N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capcitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46

34 Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115: 2630-2639

35 Cereda S, Reni M. Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2008; 26: 509-512

36 Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 2010; 30: 2905-2909

37 Katopodis O, Polyzos A, Kentepezidis N, Giassas S, Rovithi M, Bozionelou L, Kalbakis K, Vamvakas L, Mavromdis D, Georgoulias V. Second-line chemotherapy with capcitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67: 361-368

38 Ko AH, Dito E, Schilling B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest 2008; 26: 47-52

39 Reni M, Panucci MG, Passoni P, Bonetto E, Nicoletti R, Ronzoni M, Zerbi A, Staudacher C, Di Carlo V, Villa E. Salvage
chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 2004; 22: 688-696

40 Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogleman DR. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2012; 69: 425-430

41 Reni M, Berardi R, Mambrini A, Pasetto L, Cereda S, Ferrari VD, Cascini S, Cantore M, Mazza E, Grisanti S. A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2008; 62: 673-678

42 Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicolleti R, Balzano G, Passoni P, Villa E. XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res 2010; 30: 4785-4790

43 Reni M, Cereda S, Mazza E, Passoni P, Nicolleti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Ann J Clin Oncol 2008; 31: 145-150

44 Cereda S, Reni M, Rognone A, Fugazza C, Ghidini M, Ceraulo D, Brioschi M, Nicolleti R, Villa E. Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy 2011; 57: 156-161

45 Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell’Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicolleti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785-791

46 Saif MW, Poddobesteva NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 2010; 28: 186-194

47 Abu Lila AS, Ishida T, Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res 2010; 27: 1171-1183

48 Lühr JM, Haas SL, Bechtin WO, Bodoky G, Cvietkova K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II phase trial. Ann Oncol 2012; 23: 1214-1222

49 Desai N, Triew U, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Laboa E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cromophor-free, albumin-bound paclitaxel, ABI-007, compared with cromophor-based paclitaxel. Clin Cancer Res 2012; 12: 1317-1324

50 Von Hoff DD, Rannagan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Triew U, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-4554

51 Hosein PJ, Pastornik VH, Gomez CM, Macintyre J, Merchant JR, Ferrell A, Eseey M, Zayas G, Bejarano P, Lima CSR. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine-based therapy. J Clin Oncol 2010; 28 Suppl 15: abstr 4120

52 Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 529-533

53 Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holfbrook MA. Combined 5-fluorouracil and supraphysiologic radiation therapy of locally unrespectable gastrointestinal cancer. Lancet 1969; 2: 865-867

54 Blackstock AW, Tepper JE, Niedzwieki D, Hollis DR, Mayer RJ, Tempeiro MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003; 34: 107-116

55 Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, Stella PJ, Tenglin RC, Schaefer PL, Moore DF, Alberts SR. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007; 25: 2567-2572

56 Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. Natl Cancer Inst 1994; 86: 441-446

57 Safra H, Moore T, Iannitti D, Dipietrillo T, Akerman P, Ciolfi W, Harrington D, Quirk D, Rathore R, Cuff D, Valaharia J, Vora S, Savarese D, Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001; 49: 1275-1279

58 Rich T, Harris J, Abrams B, Erickson B, Doherty M, Paradelo J, Small W, Safra H, Wanebo HJ. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004; 27: 51-56

59 Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthay JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20: 2537-2544

60 Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 3843-3850

61 Oberic L, Viret F, Baey C, Ychou M, Bennouna J, Adenis A, Peillert D, Mornex F, Pignon JP, Cellier P, Berille J, Ducreux M. Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized controlled phase II trial’s planned analysis and case report of a 5.5-year disease-free survival. Radiat Oncol 2011; 6: 124

62 Cascini S, Falconi M, Valentini V, Jelic S. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v55-v58

63 Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khourana AA, Goldman B, Fenoglio-Pretisser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610

64 Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mukhaly MF, O’Reilly E, Wozniak TP, Picus J, Bhargava P, Mayer RJ, Schulsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622

65 Moore MJ, Goldstein D, Haman J, Figuer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Waldle D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Psailsynski M, Farulekar W. Erlotinib plus gemcitabine compared with
gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pére-Vergé D, Delbaldon C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825

Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pedezzoli P, Falconi M. An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs 2010; 21: 459-464

Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi A, Di Carlo V, Villa E. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2003; 19: 2679-2686

Reni M, Passoni P, Bonetto E, Balzano G, Zerbi A, Ronzoni M, Staudacher C, Villa E, Di Carlo V. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 2005; 68: 239-245

Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Muzio ND, Carlo VD, Villa E. Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial. Ann Surg Oncol 2012; 19: 2256-2263

Boeck S, Wilkowski R, Bruns CJ, Jessels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V. Oral capcitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73: 221-227

Sage EH. Terms of attachment: SPARC and tumorigenesis. Nat Med 1997; 3: 144-146

Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107: 1049-1054

Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003; 14: 3977-3988

Parkin CA, Ingham PW. The adventures of Sonic Hedgehog in development and repair. I. Hedgehog signaling in gastrointestinal development and disease. Ann J Physical Gastrointestinal Liver Physiol 2008; 294: G363-G367

Olive KP, Jacobetz MA, Copinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese Kerala, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rücker G, Grützmach R, Pilarsky C, Iseradjene H, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hrubes RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461

Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 267-272

Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A thera. Neoplasia 2008; 10: 613-623